Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$84.50
0.320.38%
Après les heures de négociation: 8:58 AM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Merck & Co Inc a un objectif de cours consensus de $118.52, basé sur les évaluations des 28 analystes. Le plus élevé est de $155 attribué par Cantor Fitzgerald le octobre 3, 2024, et le plus bas est de $84 attribué par Citigroup le mai 14, 2025. Les 3 dernières évaluations d'analystes ont été publiées par Wells Fargo, Morgan Stanley et Citigroup le juillet 30, 2025, juillet 10, 2025 et mai 14, 2025. Avec un objectif de cours moyen de $90.67 entre Wells Fargo, Morgan Stanley et Citigroup, il y a une variation implicite de 7.96% upside pour Merck & Co Inc à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Wells Fargo
Morgan Stanley
Citigroup
Cantor Fitzgerald
Guggenheim
1calculé à partir des notes des analystes
Notes d'analystes pour Merck & Co
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
07/30/2025 | 7.16% | Wells Fargo | $97 → $90 | Maintains | Equal-Weight | |||
07/10/2025 | 16.69% | Morgan Stanley | $99 → $98 | Maintains | Equal-Weight | |||
05/14/2025 | 0.02% | Citigroup | $115 → $84 | Downgrade | Buy → Neutral | |||
04/22/2025 | 1.21% | Cantor Fitzgerald | → $85 | Initiates | → Neutral | |||
04/17/2025 | 36.93% | Guggenheim | $115 → $115 | Reiterates | Buy → Buy | |||
02/18/2025 | 25.02% | Deutsche Bank | $128 → $105 | Downgrade | Buy → Hold | |||
02/12/2025 | 36.93% | Guggenheim | $122 → $115 | Maintains | Buy | |||
02/05/2025 | 33.36% | B of A Securities | $118 → $112 | Maintains | Buy | |||
02/05/2025 | 14.31% | BMO Capital | $105 → $96 | Maintains | Market Perform | |||
02/05/2025 | 36.93% | Citigroup | $125 → $115 | Maintains | Buy | |||
02/05/2025 | 26.21% | Morgan Stanley | $113 → $106 | Maintains | Equal-Weight | |||
01/28/2025 | 48.84% | Citigroup | $130 → $125 | Maintains | Buy | |||
01/21/2025 | 34.55% | Morgan Stanley | $123 → $113 | Maintains | Equal-Weight | |||
01/17/2025 | 45.26% | Guggenheim | $130 → $122 | Maintains | Buy | |||
01/13/2025 | 41.69% | Leerink Partners | $136 → $119 | Maintains | Outperform | |||
01/08/2025 | 42.88% | UBS | $125 → $120 | Maintains | Buy | |||
01/08/2025 | 30.98% | Truist Securities | $130 → $110 | Downgrade | Buy → Hold | |||
12/20/2024 | 25.02% | BMO Capital | $136 → $105 | Downgrade | Outperform → Market Perform | |||
12/10/2024 | 44.07% | B of A Securities | → $121 | Reinstates | → Buy | |||
11/15/2024 | — | Wolfe Research | — | Initiates | → Peer Perform | |||
11/07/2024 | 54.79% | Truist Securities | $132 → $130 | Maintains | Buy | |||
11/06/2024 | 54.79% | Guggenheim | $137 → $130 | Maintains | Buy | |||
11/01/2024 | 30.98% | Wells Fargo | $125 → $110 | Maintains | Equal-Weight | |||
11/01/2024 | 61.93% | BMO Capital | $150 → $136 | Maintains | Outperform | |||
11/01/2024 | 46.45% | Morgan Stanley | $130 → $123 | Maintains | Equal-Weight | |||
10/25/2024 | 54.79% | Citigroup | $140 → $130 | Maintains | Buy | |||
10/17/2024 | 36.93% | Bernstein | — | → $115 | Initiates | → Market Perform | ||
10/09/2024 | 61.93% | UBS | $142 → $136 | Maintains | Buy | |||
10/09/2024 | 57.17% | Truist Securities | $143 → $132 | Maintains | Buy | |||
10/07/2024 | 66.7% | Barclays | $142 → $140 | Maintains | Overweight | |||
10/03/2024 | 84.56% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
09/16/2024 | 84.56% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
08/29/2024 | 84.56% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
07/31/2024 | 69.08% | Barclays | $145 → $142 | Maintains | Overweight | |||
07/31/2024 | 72.65% | B of A Securities | $150 → $145 | Maintains | Buy | |||
07/31/2024 | 48.84% | Wells Fargo | $140 → $125 | Maintains | Equal-Weight | |||
07/31/2024 | 69.08% | UBS | $148 → $142 | Maintains | Buy | |||
07/11/2024 | 59.55% | Morgan Stanley | $132 → $134 | Maintains | Equal-Weight | |||
06/20/2024 | 84.56% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
06/18/2024 | 84.56% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
06/04/2024 | 84.56% | Cantor Fitzgerald | $155 → $155 | Reiterates | Overweight → Overweight | |||
04/26/2024 | 70.27% | Truist Securities | $142 → $143 | Maintains | Buy | |||
04/18/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
04/08/2024 | 70.27% | Berenberg | $140 → $143 | Maintains | Buy | |||
04/05/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
04/01/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
03/28/2024 | 69.08% | Truist Securities | $139 → $142 | Reiterates | Buy → Buy | |||
03/27/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
03/27/2024 | 60.74% | Wells Fargo | $130 → $135 | Maintains | Equal-Weight | |||
03/11/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
03/11/2024 | 23.83% | Societe Generale | → $104 | Downgrade | Hold → Sell | |||
02/29/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
02/14/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
02/05/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
02/02/2024 | 65.51% | Truist Securities | $122 → $139 | Maintains | Buy | |||
02/02/2024 | 76.22% | UBS | $135 → $148 | Maintains | Buy | |||
02/02/2024 | 54.79% | Wells Fargo | $125 → $130 | Maintains | Equal-Weight | |||
02/02/2024 | 72.65% | Barclays | $135 → $145 | Maintains | Overweight | |||
01/23/2024 | 60.74% | Barclays | $130 → $135 | Maintains | Overweight | |||
01/09/2024 | 60.74% | Cantor Fitzgerald | $135 → $135 | Reiterates | Overweight → Overweight | |||
01/04/2024 | 60.74% | TD Cowen | $125 → $135 | Upgrade | Market Perform → Outperform | |||
11/29/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
11/20/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
11/15/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
11/09/2023 | 36.93% | Deutsche Bank | → $115 | Initiates | → Buy | |||
10/27/2023 | 40.5% | Morgan Stanley | $115 → $118 | Maintains | Equal-Weight | |||
10/27/2023 | 57.17% | BMO Capital | → $132 | Upgrade | Market Perform → Outperform | |||
10/23/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
10/11/2023 | 36.93% | Morgan Stanley | $116 → $115 | Maintains | Equal-Weight | |||
10/06/2023 | 45.26% | Truist Securities | → $122 | Reiterates | Buy → Buy | |||
10/04/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
10/02/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
09/05/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
08/22/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
08/02/2023 | 45.26% | Truist Securities | $116 → $122 | Maintains | Buy | |||
08/02/2023 | 38.12% | Morgan Stanley | $109 → $116 | Maintains | Equal-Weight | |||
07/20/2023 | 38.12% | Truist Securities | $118 → $116 | Maintains | Buy | |||
07/14/2023 | 46.45% | HSBC | → $123 | Initiates | → Hold | |||
07/11/2023 | 29.79% | Morgan Stanley | $109 → $109 | Reiterates | Equal-Weight → Equal-Weight | |||
05/30/2023 | 60.74% | Cantor Fitzgerald | → $135 | Reiterates | Overweight → Overweight | |||
05/01/2023 | 53.6% | Atlantic Equities | $127 → $129 | Maintains | Overweight | |||
05/01/2023 | 54.79% | Barclays | $128 → $130 | Maintains | Overweight | |||
04/13/2023 | 54.79% | Citigroup | $105 → $130 | Upgrade | Neutral → Buy | |||
04/11/2023 | 47.65% | Guggenheim | $123 → $124 | Maintains | Buy | |||
04/10/2023 | 54.79% | Mizuho | → $130 | Reiterates | → Buy | |||
03/17/2023 | 54.79% | Mizuho | → $130 | Reiterates | → Buy | |||
03/13/2023 | 36.93% | Wells Fargo | $120 → $115 | Downgrade | Overweight → Equal-Weight | |||
03/10/2023 | 54.79% | Berenberg | $125 → $130 | Maintains | Buy | |||
03/07/2023 | 50.03% | Credit Suisse | $125 → $126 | Maintains | Outperform | |||
03/07/2023 | 51.22% | Atlantic Equities | $122 → $127 | Maintains | Overweight | |||
03/06/2023 | 48.84% | Jefferies | → $125 | Initiates | → Buy | |||
02/23/2023 | 48.84% | JP Morgan | $120 → $125 | Maintains | Overweight | |||
02/22/2023 | 51.22% | Wolfe Research | → $127 | Upgrade | Peer Perform → Outperform | |||
02/13/2023 | 48.84% | Credit Suisse | $120 → $125 | Maintains | Outperform | |||
02/03/2023 | 42.88% | Wells Fargo | $125 → $120 | Maintains | Overweight | |||
02/03/2023 | 17.88% | Morgan Stanley | $100 → $99 | Maintains | Equal-Weight | |||
02/03/2023 | 40.5% | Truist Securities | $106 → $118 | Maintains | Buy | |||
02/03/2023 | 45.26% | SVB Leerink | $120 → $122 | Maintains | Outperform | |||
01/23/2023 | 42.88% | SVB Leerink | $112 → $120 | Maintains | Outperform | |||
01/04/2023 | 54.79% | B of A Securities | $110 → $130 | Upgrade | Neutral → Buy |
FAQ
Quel est le cours indicatif de l'action Merck & Co (MRK) ?
Le dernier objectif de prix pour Merck & Co (NYSE:MRK) a été rapporté par Wells Fargo le juillet 30, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $90.00 s'attendant à ce que MRK se rise dans les 12 prochains mois (un possible changement de 7.16% upside). 32 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Merck & Co (MRK) ?
La dernière note d'analyste pour Merck & Co (NYSE:MRK) a été fournie par Wells Fargo, et Merck & Co maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour Merck & Co (MRK) ?
La dernière amélioration pour Merck & Co Inc a eu lieu le janvier 4, 2024 lorsque TD Cowen a augmenté leur objectif de prix à $135. TD Cowen avait précédemment a market perform pour Merck & Co Inc.
Quand a eu lieu la dernière dégradation pour Merck & Co (MRK) ?
La dernière réduction pour Merck & Co Inc a eu lieu le mai 14, 2025 lorsque Citigroup a changé leur objectif de prix de $115 à $84 pour Merck & Co Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Merck & Co (MRK) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Merck & Co, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Merck & Co a été déposée le juillet 30, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers juillet 30, 2026.
La note d'analyste pour Merck & Co (MRK) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Merck & Co (MRK) était un maintenu avec un objectif de prix de $97.00 à $90.00. Le prix actuel de Merck & Co (MRK) est de $83.99, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.